In the treatment of head and neck squamous cell carcinomas nowadays we can see a worldwide effort to prolong survival with a satisfactory quality of life. This requires earlier detection of disease and also new treatment strategies -new chemotherapeutic regimens, intensity-modulated radiotherapy, and targeted treatment. The latter is especially promising when combined with radiotherapy. Monoclonal antibody against epidermal growth factor receptor (EGFR) demonstrated good antitumor activity in the first line treatment of locally advanced head and neck cancers [1] . EGFR (HER1, c-erb B1) is a member of the receptors family. It is a well -characterizedproto-oncogene that is present in many cancer site where itpromotes tumor progression. It comprises an extracellular ligand-binding domain, a transmembrane region, and an intracellular domain which includes a kinase domain and autophosphorylation sites. EGFR is ubiquitouslydistributed in normal epithelial tissues and is over-expressed in a wide range of cancers; in HNSCC approximately in 80 % [2, 3] . EGFR plays a critical role in the control of cellular proliferation, differentiation and survival. The binding of ligand to the EGFR triggers EGFR homodimerisation or heterodimerisation of the EGFR with another receptor from its family, results in autophosphorylation and downstream signaling [4] . Genetic abnormalities in the EGFR signaling pathway in HNSCC were not yet sufficiently described. The effect of EGFR inhibitors depends on the presence of genetic alteration in the EGFR signaling pathway [5] [6] [7] . Therefore it is necessary to seek markers of response to this therapy at the level of an individual genetic profile. Predicting the outcome in EGFR-targeted therapies is complex and involves genetic and clinical characteristics. In addition to the predictive value of non-smoking, and the higher intensity of skin reaction [8] , predictive markers appear to exist at the level of specific genetic aberrations causing deregulation of the cell cycle. The influence of the tyrosinkinase domain of EGFR on positive response to the treatment with extracellular inhibitors has not been elucidated yet [9, 10] . Constitutive activation of intracellular transducers in the EGFR signaling pathway (KRAS mutation or STAT-3 mutation), loss of the extracellular EGFR inhibitor binding site (EGFRvIII mutation), activation of EGFR-independent tumor angiogenesis (overexpression of VEGF) or altered activation of alternative tyrosinkinase receptors are among promising negative predictors [11] . In many studies, resistance to extra-and intracellular inhibitors was proven during continuous activation of the MAPK pathway [11] [12] [13] . In this context, a presence of activating KRAS mutation, which is typical of smokers, has a negative predictive value in various types of tumors, e.g. colorectal cancer [14, 15, 18] . EGFRvIII mutation (EGFR variant with deletion in exons 2-7) is found only in tumor cells. Such a mutated receptor lacks an extracellular domain; therefore extracellular inhibitors cannot bind to it. However, EGFRvIII is able to dimerize even without constitutive activation by ligand binding, and its moderate degree of auto-phosphorylation is sufficient for activation of the signaling pathway but insufficient for induction of its internalization (and down-regulation).
The aim of the present study was to analyze EGFR gene expression, and EGFR and KRAS mutational status in the correlation with treatment response to targeted therapy combined with radiotherapy in patients with advanced HNSCC.
Patients and methods
Patients.A prospective clinical study include 83 patients with verified locoregional advanced HNSCC. 29 patients were Cetuximab-treated in two tertiary centers. Remaining 54 patients were screened, and the sample for genetic analysis was taken, but Cetuximab treatment was not started due to not fulfilling inclusion criteria (n=36) or noncompliance (n=4) or for organizational reasons (n=10) or for allergic reaction (n=4). Inclusion criteria comprised a good general condition without allergy (ECOG 0,1), age up to 65 years, absence of serious Table 1 .
Methods.The recorded data were age, gender, tumor location, TNM classification, histopathological grading, therapeutic response, toxicity according to WHO, event-free survival (EFS -interval between treatment and relapse or progression of the disease) and overall survival (OS). Tumor samples were taken before treatment mostly from peripheral active parts of tumors and were fixed in RNA Later (Qiagen) and frozen. EGFR and GAPDH gene expressions and EGFRvIII mutations were detected in RNA by the RT-PCR method [16, 17] . Total RNA from RNA Later (Qiagen) fixed tissues were purified by the phenol-chloroform method using TRI Reagent (Molecular Research Center) according to the manufacturer's instructions. For reverse transcription, 3 μg of total RNA was pre-incubated with Random Primers (Promega) and then reverse transcribed using RevertAid Moloney Murine Leukemia Virus reverse transcriptase (Fermentas). To amplify cDNA of the epidermal growth factor receptor 1 (EGFR1, NM_005228), epidermal growth factor receptor vIII (EGFRvIII, NM_005228) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, NM_002046) (10), the following set of primers and probes were used: EGFRfw 5'-ACTTCAAAAACTGCACCTCCAT-3', EGFR-rev 5'-AATCAGCAAAAACCCTGTGATT-3' and EGFR-probe 5'-ACATCCTGCCGGTGGCATTTAGG-3' BHQ1-HEX (149 bp); EGFRvIII-fw 5'-AGTCGGGCTCTGGAGGAA-3' , EGFRvIII-rev 5'-GCCGTCTTCCTCCATCTCATA-3' and EGFRvIII-probe 5'-ATCACGGCTCGTGCGTCCG-3' BHQ1-HEX (102 bp); GAPDH-fw 5'-GAAGATGGTGAT-GGGATTTC -3' , GAPDH-rev 5'-AGTCGGGCTCTGGAGGAA -3' and GAPDH-probe 5'-CAAGCTTCCCGTTCTCAGCC -3' BHQ1-FAM (226 bp) (Generi-Biotech).
To analyze the EGFR1, GAPDH and EGFRvIII mRNA copies, a quantitative real-time polymerase chain reaction (qPCR) was performed in three 25 μl reactions containing 1 U of HotStart Taq Polymerase, 3 mM MgCl 2 , 10x PCR buffer (AB Gene), 200 μM dNTPs (Promega), 100 ng of cDNA, and either 400 nM EGFR-fw, 400 nM EGFR-rev, 200 nM EGFR-probe, or 300 nM GAPDH-fw, 300 nM GAPDH-rev, 200 nM GAPDH-probe, or 400 nM EGFRvIIIfw, 400 nM EGFRvIII-rev, 200 nM EGFRvIII-probe and using Rotor Gene 3000 (Corbett Research). The optimized thermal profile for EGFR1 amplification was initiated with 15-min. polymerase activation at 96°C, followed by 50 cycles of 95°C for 15 s and 62°C for 15 s, for GAPDH amplification 50 cycles of 95°C for 1 5s and 60°C for 30 s and for EGFRvIII 50 cycles of 95°C for 15 s and 61°C for 12 s. The presence of the truncated EGFRvIII gene was subsequently verified by post-PCR electrophoresis using Agilent 2100 Bioanalyzer DNA chips (Agilent). 
Results
Patient characteristics.Twenty-nine patients were included in the study -24 men and 5 women. Half of the cohort (14 patients) were under 55 years of age, while 15 patients were over 55 years old. All patients had advanced disease (clinical stage III and IV). Almost 60% of patients had grade 2 tumor, 31% grade 3 and 10% grade 1 (Table 1) . Tumors were located in the oral cavity (6.9%), oropharynx (65.5%), hypopharynx (17.3%) and larynx (10.3%). Five (17.2%) patients were treated in stage III and 24 (82.8 %) in stage IV. Overall survival (OS) and event-free survival (EFS) were assessed: the median follow-up was 21.7 months, the 2-year OS was 75%, and seven patients died (Graph 1). Both survival parameters were also assessed for various types of patient stratification (gender, age, clinical stage, grade, genes activity, and mutations). No statistically significant differences were found however in this analysis. Overall, a good treatment response was recorded during the study. Complete remission was achieved in 80% of patients, another 10% had partial remission, and only 10% of patients did not respond to the treatment. Serious adverse effects (grades 3 and 4) associated with toxicity on the skin occurred in 44.8% of patients, while serious mucosal toxicity was recorded in 34.5% of patients (Table 1) . EGFR expression and KRAS and EGFR mutational status were correlated with treatment response to anti-EGFR therapy combined with radiotherapy (Table 2) . EGFR Gene expression.GAPDH and EGFR gene levels were assessed. Median values were 3.1x10 8 GAPDH gene copies per µg of RNA, 8x10 6 EGFR gene copies per µg of RNA and 0.14 for the EGFR/GADPH ratio. Treatment results were analyzed in relation to molecular characteristics of patients. Patients who achieved a complete response had significantly higher expression of the EGFR gene than patients with a partial response or without a response ( Table  2 , p=0.02). The relation between treatment result and EGFR gene expression normalized to GAPDH was not statistically confirmed. A statistically significant relationship (p<0.05) of EGFR/GADPH for mucosal toxicity was found (data not shown).
EGFRvIII mutation analysis.EGFRvIII mutation was found in 20.7% (6 out of 29) patients. The expected significant association between this mutation and treatment response to anti-EGFR therapy (Cetuximab) was not found. No significant difference was found between different clinical characteristics (age, clinical stage, grade, toxicity) and EGFRvIII mutation with the exception of gender (EGFRvIII was not found in women). EGFR mutation analysis.27 patients (93.1 %) had wildtype EGFR gene; deletion in exon 19 was found in two patients. Presence of EGFR mutation (deletion in exon 19) was associated with a worse prognosis -presence of recurrence and/or progression and/or death (Table 2, p=0.033) and with no response to treatment (Table 2, p=0.042).
KRAS mutation analysis.Most of the patients (82.8%) had wild-type KRAS. P.Gly12Cys and p.Gly12Val mutation was found in three patients and one patient, respectively. Presence of p.Gly12Val mutation in the KRAS gene was associated with no response to treatment; this statement is, nevertheless, based on experience with one patient only (Table 2, p=0.027). In total, one of two mutations tested (deletion in exon 19 and KRAS mutation) was found in 6 patients (Table 1) .
No significant difference was found between different clinical characteristics (gender, age, clinical stage, grade, toxicity) and any of these mutations.
Discussion
The treatment response (CR 80 %) of radiotherapy combined with Cetuximab in our set of patients is consistent with Bonner´s et al. report in which patients have good therapeutical results [1] and with experimental data of Gurtner et al. [18] . The knowledge of EGFR expression and EGFR and KRAS mutational status becomes clinically important with the wider use of anti-EGFR therapies in HNSCC. In our study, patients who achieved a complete response had significantly higher number of EGFR gene mRNA copies than patients wit partial remission only or patients without a treatment response. There is experimental evidence that EGFR amplification and elevated EGFR expression levels in HNSCC may result in a less favorable prognosis [18, 20] , but clinical studies are inconclusive [21] . A high EGFR gene copy number could be a positive predictive marker for treatment response [2, 19] . There are discrepancies between the results of studies comparing the EGFR amplification and the EGFR expression in various tumors: some authors have reported the correlation [22, 23] while others have not [24] . The detection of the EGFR expression depends partly on the specificity and sensitivity of available immunohistochemical sets [24] . Furthermore, there are differences of the EGFR expression within a tumor: the highest expression, e.g. the most active parts, can be found in the periphery, whereas in central parts the expression could be very low or negative. FISH has been used as a reference method for the assessment of gene amplification for many years; however, there are several ways to analyze gene expression by FISH [2, 25, 26] and not all authors distinguish true gene amplifications from chromosomal polysomy. This could be a reason why there are studies with a low percentage of FISH positivity, e.g. 17% [2] , whereas other studies present 58% [27] or 63% [19] in HNSCC. In chemotherapy-treated non-small-cell lung cancer patients, the EGFR gene copy number was positively associated with protein level but none of the features were predictive for either treatment response or survival [28] . The amplification of the EGFR gene is the most frequent alteration of glioblastoma multiforme and confers advantages of growth and invasiveness and radio-and chemo resistance on tumor cells. The FISH method is commonly used to determine gene copy numbers, but the quantitative real-time polymerase chain reaction (qPCR) used in our study can obtain a gene copy number, is less expensive, and makes data interpretation more reliable because of use of a large area of tumors [2] . The mutations of the tyrosine kinase domain of the EGFR gene in the exons 19 and 21 are known to affect sensitivity to the EGFR inhibitors; at the same time, they can be used as positive predictive markers during therapy with intracellular inhibitors [6, 29, 30] . Some data suggest that EGFR mutations do not confer sensitivity to the monoclonal antibody Cetuximab. Cetuximab binds to the cell-surface receptor, whereas the kinase inhibitors bind to the intracellular tyrosine kinase domain; therefore in EGFR mutant cell lines Cetuximab has relatively little effect [11] . KRAS mutation (p.Gly12Cys) was found in our study in 3 patients out of 29 (10.3%) and KRAS mutation (p.Gly12Val) was found in one patient out of 29 (3.4%). KRAS mutation was connected with an absence of response to Cetuximab therapy combined with radiotherapy. KRAS gene mutation is known as a negative prognostic marker [18] . This mutation is strongly associated with a negative response to the EGFR inhibitors and it is used as a negative predictive marker in some types of tumors [14, 31] . The KRAS gene mutation is rare in HNSCC [32] . Van Damme et al. did not find any KRAS mutation by sequencing in a set of 24 patients with tonsil squamous cell carcinoma. The authors conclude that KRAS mutation analysis is not useful as a screening test for sensitivity to anti-EGFR therapy in tonsil squamous cell carcinoma [26] . Hoa et al. supposed that amplification of wild-type KRAS promotes growth of HNSCC [33] .
EGFRvIII has been examined only in a small amount of HNSCC tumors [20] . In our study the rate of EGFRvIII detected at the mRNA level by RT-PCR was 20.7 % (6 out of 29). Sok et al. found EGFRvIII expression established by immunohistochemistry in 42 % of HNSCC tumors (14 out of 33), and in nearly half of HNSCC tumors established by RT-PCR [20] . Ji et al. [34] found EGFRvIII mutation in 5% (3 out of 56) in squamocellular cancer and not in lung adenocarcinomas. Chau et al. [35] found EGFRvIII mutation in 40 % (22 out of 53) in HNSCC and it appeard to be biomarker associated with better disease control in recurrent or metastatic disease, but no difference was seen between erlotinib-treated versus nonerlotinib treated patients. In our study we could not prove an influence of EGFRvIII on treatment response to EGFR targeted therapy. In HNSCC, resistance to monoclonal antibodies and decreased response to cisplatin was demonstrated in the presence of EGFRvIII [36] . Sok et al. proved that EGFRvIII contributes to enhanced growth and resistance to targeting wild-type EGFR [20] .
Conclusions
Our data suggest that KRAS mutation (p.Gly12Val) and somatic EGFR mutation located in exon 19 may contribute to the limited clinical response to therapy with Cetuximab + radiotherapy. Higher EGFR gene expression serves as an independent indicator of good clinical response to Cetuximab therapy combined with radiotherapy. A correlation between EGFRvIII and clinical response to EGFR targeted treatment was not proven. Our results are limited by the size of the evaluated sample and should be verified on a larger cohort of HNSCC patients.
